Amgen's Ph3 rare disease success from $27.8B Horizon acquisition, Annexon sells $125M in common stock, Telix Pharmaceuticals plans $200M IPO, and Finland's taking no chances with bird flu.
Lykos gets an FDA advisory thumbs down, BridgeBio & Viking Therapeutics deliver positive results but their stocks drop anyway, AstraZeneca's "armoured" CAR-T, and Summit cashes in $200M from an institutional investor.
Eli Lilly buys an ALS asset, Caribou touts partial HLA matching for allogeneic cell therapies, Jazz has "unprecedented" long-term data, and Merck discusses a post-Keytruda future.
GSK's ADC comeback story, Sanofi & Regeneron receive mixed signals, Moderna gets RSV vaccine approval, and an MDMA treatment lands FDA scrutiny.
🧬 Winners, Losers, and Upcoming Earnings Calls
Merck gets beaten at it’s own game, BMS lands another CAR-T indication, Otsuka dives into digital therapeutics, and "hub-and-spoke" biotech raises $73M.
FDA approvals for Amgen and Tris Pharma, BMS' $80M global licensing spend, BioNTech continues Africa push with $145M, and Novo Nordisk blames the American Healthcare System
Pfizer naps a Priority Review Voucher, 3 separate $1B+ acquisitions, Insmed stock doubles on Ph3 results, and Takeda begins restructuring with 600+ layoffs.
ASCO news up the wazoo, CAR-T attacks solid tumors, the first reported case of diabetes cured by cell therapy, and positive Ph1/2 data turns sour on safety profile.
Takeda's sticky $1.2B partnership, two new funds totally $350M+, Adderall no longer in short supply, two big pharmas ordered to pay Hawaii nearly $1B
Pfizer plans another $1.5B in cuts, biotech launches with aim to shed fat (but not muscle), Otsuka ditches an Alzheimer's med, and Novo Nordisk is on fire (again).
